Positive USFDA Meeting - Technegas sales expected in 2019
Filed with ASX · · 2 pages · English
Story so far
Earlier from Cyclopharm
- Cyclopharm 2018 First Half Preliminary Headline Update
- CYC 2018 AGM Presentation
- Better Defining Airways Disease with Technegas
- Cyclopharm Acquires Scandinavian Distribution Business
- 40 Patient Milestone Achieved For Technegas USFDA Trial
Later from Cyclopharm
- CANM Endorses Technegas
- CYC Update - R&D Tax Incentive, USFDA, German Litigation
- Announcement of buy-back - Appendix 3C
- CYC Half Yearly Reports and Accounts
- CYC Business Update
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm